Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

CorMedix Inc.

NASDAQ: CRMD · Life Sciences · 8 alerts · CIK 1410098

Share price
$4.82Close, Nov 16
Market cap
$383M
Shares outstanding
79.54MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All CorMedix Inc. filings on SEC EDGAR ↗

7:31 AM ET Form 4
Insider Buying

CorMedix CEO Joseph Todisco Buys $391K of Stock

Joseph Todisco, CEO, bought 80,000 shares of CorMedix Inc. at $4.89 a share, worth $391K in total on Nov 13, 2026. Shares held after the trade: 854,749 (+10.3%).

Value
$391K
Shares
80,000
Price
$4.89
Role
CEO
Holding change
+10.3%
Trade date
Nov 13, 2026
6:11 AM ET 8-K
M&A Deal

CorMedix M&A Deal with Heron Therapeutics, Inc.

CorMedix Inc. announced a definitive agreement to acquire substantially all of the assets of Heron Therapeutics, Inc., including both commercial and pipeline assets. The acquisition is intended to provide scale and diversification to CorMedix's institutional care growth strategy and remains subject to Heron stockholder approval and regulatory clearance.

Counterparty
Heron Therapeutics, Inc.
8:22 AM ET 10-Q
Financial Results

CorMedix Q3 2026 Results: Net Loss of $14.7M

CorMedix Inc. reported net income of $49.9 million for the nine months ended September 30, 2026, a decrease from $149.0 million in the prior year period, primarily due to higher operating expenses and a significant tax benefit recorded in 2025. Total revenue and grant income grew to $283.9 million for the nine-month period, driven by product sales and new grant income.

Key figure
Net loss $14.7M
8:00 AM ET 8-K
Financial Results

CorMedix Financial Results

CorMedix reported Q3 2026 consolidated revenue of $54.5 million and a net loss of $14.7 million, while maintaining its full-year 2026 revenue guidance. The company also highlighted its pending acquisition of Heron Therapeutics assets and a new $150 million term loan facility to support the transaction and operations.

Term
Q3 2026

“CorMedix will be entering 2027 with two meaningful potential growth drivers. First, our pending acquisition of the Heron assets adds four commercial products used in institutional settings of care and is expected to be immediately accretive to earnings and free cash flow upon closing.”

Joseph Todisco, Chairman & Chief Executive Officer
5:16 PM ET 8-K
M&A Deal

CorMedix M&A Deal with Heron Therapeutics, Inc.

CorMedix Inc. has entered into a definitive asset purchase agreement to acquire substantially all of the assets of Heron Therapeutics. The transaction will be funded in part through a new term loan facility with Pharmakon and the issuance of CorMedix common stock as consideration. The deal is expected to be accretive to earnings and free cash flow while providing operating cost synergies.

Counterparty
Heron Therapeutics, Inc.
7:50 AM ET 8-K
M&A Deal

CorMedix Signs $145M M&A Deal with Heron Therapeutics, Inc.

CorMedix Inc. has entered into a definitive agreement to acquire substantially all assets of Heron Therapeutics for $145 million in cash and 14,583,333 shares of common stock. The deal adds four commercial-stage products (ZYNRELEF, APONVIE, CINVANTI, and SUSTOL) to CorMedix's institutional care portfolio and includes up to $55 million in potential earn-out payments. To fund the transaction, CorMedix secured a new $75 million senior secured term loan facility from Pharmakon Advisors.

Value
$145M
Counterparty
Heron Therapeutics, Inc.
7:40 AM ET 8-K
Business Update

CorMedix Business Update

CorMedix provided a business update reporting a cash position of approximately $355 million as of September 30, 2026, and reaffirmed its full-year 2026 revenue guidance. The company also addressed the CMS 2027 ESRD PPS final rule regarding DefenCath reimbursement, projecting that the average 2027 Add-on rate will be more than double the current rate.

8:00 AM ET 8-K
Business Update

CorMedix Business Update

CorMedix announced that the FDA has accepted for filing a supplemental New Drug Application (sNDA) for REZZAYO (rezafungin for injection) for the prophylaxis of invasive fungal disease. The FDA granted Priority Review for the application, which is supported by positive Phase III ReSPECT study data, and set a PDUFA target action date in Q1 2027.

Counterparty
FDA

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.